Wells Fargo & Company Issues Positive Forecast for Heartflow (NASDAQ:HTFL) Stock Price

Key Points

• Wells Fargo raised Heartflow’s price target to $39 from $37 and maintained an “overweight” rating, while the broader analyst consensus is “Moderate Buy” with a $42 target.
• Heartflow reported stronger-than-expected second-quarter results, with a $0.07 per-share loss versus the expected $0.22 loss and revenue of $64.08 million, up 47.7% year over year. The stock subsequently rose 31.4% to $40.73.
• Growth prospects remain positive, but profitability is unresolved: management raised its 2026 revenue outlook to $246 million–$250 million, although analysts still expect a full-year loss and insiders have sold shares under pre-arranged trading plans.

Heartflow (NASDAQ:HTFL - Get Free Report) had its price objective increased by equities research analysts at Wells Fargo & Company from $37.00 to $39.00 in a report released on Friday,Benzinga reports. The firm presently has an "overweight" rating on the stock. Wells Fargo & Company's price objective points to a potential downside of 4.26% from the company's current price.

Several other equities analysts have also recently weighed in on the stock. Freedom Capital raised shares of Heartflow to a "strong-buy" rating in a research note on Tuesday, June 30th. Piper Sandler reissued an "overweight" rating and issued a $45.00 price objective on shares of Heartflow in a research report on Friday. Stifel Nicolaus lifted their price target on Heartflow from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Friday. Weiss Ratings upgraded shares of Heartflow from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, August 7th. Finally, Morgan Stanley set a $40.00 target price on shares of Heartflow in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $42.00.

Heartflow Trading Up 31.4%

Shares of Heartflow stock traded up $9.72 during mid-day trading on Friday, reaching $40.73. 3,975,411 shares of the stock were exchanged, compared to its average volume of 1,434,520. The firm has a 50-day simple moving average of $28.80 and a 200 day simple moving average of $27.70. Heartflow has a fifty-two week low of $20.13 and a fifty-two week high of $42.95. The company has a market cap of $3.51 billion and a price-to-earnings ratio of -13.18.

Heartflow (NASDAQ:HTFL - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.15. The company had revenue of $64.08 million during the quarter. Heartflow's revenue was up 47.7% on a year-over-year basis. On average, research analysts predict that Heartflow will post -0.82 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO John C.M. Farquhar sold 38,900 shares of the business's stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $35.00, for a total transaction of $1,361,500.00. Following the completion of the sale, the chief executive officer owned 457,935 shares in the company, valued at $16,027,725. The trade was a 7.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 9,219 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $28.34, for a total value of $261,266.46. Following the completion of the transaction, the insider owned 78,731 shares in the company, valued at approximately $2,231,236.54. This represents a 10.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 115,805 shares of company stock worth $3,530,609. 7.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Heartflow

A number of hedge funds and other institutional investors have recently modified their holdings of HTFL. Caitong International Asset Management Co. Ltd purchased a new position in shares of Heartflow in the 4th quarter worth about $27,000. Russell Investments Group Ltd. purchased a new stake in Heartflow in the fourth quarter worth $45,000. Essential Partners LLC bought a new stake in shares of Heartflow in the first quarter valued at $57,000. Legal & General Group Plc purchased a new position in shares of Heartflow during the 3rd quarter valued at $59,000. Finally, Strs Ohio bought a new position in shares of Heartflow during the 4th quarter worth $99,000.

Key Stories Impacting Heartflow

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Strong Q2 performance: Heartflow reported a loss of $0.07 per share, beating the $0.22 expected loss by $0.15. Revenue reached $64.08 million, an increase of 47.7% from the prior-year quarter. Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
• Positive Sentiment: Raised 2026 outlook: Management now expects full-year revenue of $246 million to $250 million, well above the approximately $230.1 million analyst consensus. The higher forecast reinforces expectations for continued demand for Heartflow’s AI-based coronary artery disease diagnostic technology.
• Positive Sentiment: Analyst upgrade: Stifel Nicolaus raised its price target from $40 to $45 and upgraded the stock to “Buy,” implying additional upside based on the reported reference price. This adds further momentum following the earnings release. Benzinga
• Neutral Sentiment: Profitability remains a concern: Although the quarterly loss was narrower than expected and significantly improved from the prior year, Heartflow remains unprofitable. Analysts currently expect a full-year loss of approximately $0.82 per share.
• Negative Sentiment: CEO stock sale: Chief Executive John C.M. Farquhar sold 22,562 shares valued at approximately $638,730, reducing his direct holdings by 4.92%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which reduces its signaling value, but repeated insider selling could still weigh modestly on sentiment. Heartflow CEO Sells Shares

About Heartflow

HeartFlow, Inc NASDAQ: HTFL is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source